<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03612921</url>
  </required_header>
  <id_info>
    <org_study_id>17300205</org_study_id>
    <nct_id>NCT03612921</nct_id>
  </id_info>
  <brief_title>Oral Amantadine, IV Amantadine and Hemodynamic Response to Laryngoscopy</brief_title>
  <official_title>Oral Amantadine Versus IV Amantadine to Attenuate the Hemodynamic Response to Laryngoscopy, Tracheal Intubation and Surgical Incision and Their Effect on β-endorphin: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study will be undertaken-to evaluate the effect of oral amantadine versus IV amantadine
      premedication on the hemodynamic response to laryngoscopy ,tracheal intubation and surgical
      incision and their effect on β-endorphins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Direct laryngoscopy and passage of endotracheal tube through the larynx is a noxious
      stimulus, which can provoke untoward response in the cardiovascular, respiratory and other
      physiological systems .Amantadine is a non-competitive NMDA receptor antagonist, and compared
      to ketamine, it is well tolerated with fewer side effects (mainly dizziness, sedation, and
      dry mouth). Amantadine's formulation permits the oral route for drug delivery, as well as the
      IV route. The side-effects profile of amantadine via all routes seems not to be harmful in
      appropriate dosages.. Amantadine has been clinically used as an antiviral drug, for dementia,
      and in the treatment of Parkinson's disease and spasticity. It is a non-competitive NMDA
      receptor antagonist, and compared to ketamine, it is well tolerated with fewer side effects
      (mainly dizziness, sedation, and dry mouth). Amantadine's formulation permits the oral route
      for drug delivery, as well as the IV route. The side-effects profile of amantadine via all
      routes seems not to be harmful in appropriate dosages.

      In the central nervous system, beta-endorphins bind mu-opioid receptors and exert their
      primary action at presynaptic nerve terminals. However, instead of inhibiting substance P,
      they exert their analgesic effect by inhibiting the release of GABA, an inhibitory
      neurotransmitter, resulting in excess production of dopamine.

      this study will be undertaken-to evaluate the effect of oral amantadine versus IV amantadine
      premedication on the hemodynamic response to laryngoscopy ,tracheal intubation and surgical
      incision and their effect on β-endorphins.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the effect of oral amantadine versus IV amantadine premedication on laryngoscopy and tracheal intubation on β-endorphins .</measure>
    <time_frame>baseline( before medication) , 5 minutes before induction of anaesthesia, 3 minutes after induction , 5 minutes after tracheal intubation and 5 minutes after skin incision</time_frame>
    <description>changes of the mean arterial blood pressure (mmhg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the effect of oral amantadine versus IV amantadine premedication on the hemodynamic response to surgical incision</measure>
    <time_frame>2 blood samples one just before medication and the second after 10 minutes after skin incision</time_frame>
    <description>β-endorphins level in the blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intubation, Intratracheal</condition>
  <arm_group>
    <arm_group_label>oral group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patients will receive oral amantadine sulfate using the dose 100 mg 90 minute prior to the surgery and infusion of100cm I.V saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I.V group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patients will receive 100 mg I.V amantadine sulfate infusion over 60minute prior to the surgery and placebo tablet 90 minute prior to the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group (group C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the patients will receive placebo tablet 90 minute prior to the surgery and infusion of 100cm I.V saline over 60minute prior to the surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral Amantadine sulfate</intervention_name>
    <description>oral amantadine</description>
    <arm_group_label>oral group</arm_group_label>
    <other_name>amantadine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>i.v Amantadine Sulfate</intervention_name>
    <description>intra venous amantadine</description>
    <arm_group_label>I.V group</arm_group_label>
    <other_name>PK-Merz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo tablet</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>control group (group C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I&amp;II

          -  the age range 20-55 years scheduled for elective back surgery(laminectomy, discectomy
             and spinal canal stenosis)

        Exclusion Criteria:

          -  Patient refusal

          -  Patients with ASA score III (with chronic kidney, lungs, Gastrointestinal tract,
             liver, or cardiovascular diseases)

          -  Pregnant or breastfeeding women.

          -  Allergy to any of the study medications and taking medications that could
             significantly interact with amantadine (tramadol, atropine, antipsychotic medications)

          -  DM, thyroid disease any endocrine disease

          -  Suspected difficult intubation or intubation time more than 30 second.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghada Abu El Fadl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut, Assiut governorate, Egypt, 715715</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghada Abu El Fadl, MD</last_name>
    <phone>01005802086</phone>
    <email>ghadafadl77@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>amani abd elwahab, MD</last_name>
    <phone>01004610623</phone>
    <email>amanihassan1978@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut university hospitals</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghada Abu El Fadl, MD</last_name>
      <phone>01005802086</phone>
      <email>ghadafadl77@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>amani abd elwahabMD, MD</last_name>
      <phone>01004610623</phone>
      <email>amanihassan1976@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ghada Mohammed AboelFadl</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>oral amantadine</keyword>
  <keyword>IV amantadine</keyword>
  <keyword>tracheal intubation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

